1All patients with positive or unknown estrogen receptor status were administered tamoxifen.
2The tumor cells were positive for estrogen receptor and negative for Cdx-2.
3Those with estrogen receptor-positive MBC had to have progressed on endocrine therapy.
4Forty-nine of these women had estrogen receptor-negative tumors, a poor prognostic sign.
5These tumors were estrogen receptor negative and showed no mitogenic response to estradiol.
6Results were consistent in both estrogen receptor-positive and estrogen receptor-negative tumors.
7There was no heterogeneity for any association by estrogen receptor status.
8The activation of estrogen receptor by cyclin D1 is not inhibited by anti-estrogens.
9So-called estrogen receptor (ER)-negative tumors account for about one-quarter of breast cancers.
10Medical records were reviewed to ascertain clinicopathological parameters, including estrogen receptor status and survival.
11Risk from both alleles was confined to estrogen receptor-positive tumors.
12These findings appeared to be independent of estrogen receptor status.
13FHL-1 represses the translation and transcription of estrogen receptor-responsive genes through down-regulating AKT activation.
14The outcomes were breast cancer overall and by estrogen receptor (ER) status.
15Staining with basal markers for estrogen receptor, progesterone receptor, and HER2 usually shows negative results.
16Both estrogen receptor-dependent and -independent mechanisms will be described.
Translations for estrogen receptor